Most device quality teams audit their own factories and their critical component suppliers. Fewer apply the same scrutiny to the contract laboratory that generated the bench, biocompatibility, or cybersecurity testing sitting inside a 510(k). FDA has now spent nearly three years telling manufacturers that this is a gap, and the warnings have become more specific. In February 2024, FDA's device center sent a letter to industry describing an increasing number of third-party tes
FDA's draft guidances would make eSTAR mandatory for PMAs and IDEs. Here's what they require, what's still open, and the Nov 17 and Dec 28 comment deadlines.
FDA used release notes and version logs to cite three software changes in a warning letter. Here's what it means for SaMD change control and 510(k) decisions.